

CoNexi Vision
785 Mamaroneck Ave,
White Plains, NY 10605

Cyril Eleftheriou
T 914-338-9430
Cye4002@med.cornell.edu



Switching the light **ON**

Industry:

Pharma/ Biotech /Medical Device

Management:

Cyril Eleftheriou, PhD
Postdoctoral Fellow in retinal
physiology, Weil Cornell Medicine,
Burke Neurological Institute, Founder

Botir Sagdullaev, PhD
Associate Professor of Neuroscience,
Weil Cornell Medicine, Associate
Director, Burke Neurological
Institute, Founder

Board: TBD

Number of Employees: 2

Finance:

Accountant: TBD

Funding to date:

Founders: \$20k

Financing sought: \$4M

- Prototype development: \$2M
- Clinical trial for AMD and DR treatments
- Legal fees
- Regulatory fees
- Operating Costs

IP:

- PPA filed on drug delivery device
Plan to file 3 more patents
- Gene therapy & algorithms

Legal: TBD

Business Description / Company Background:

CoNexi vision is developing DopaSight, an artificial dopamine neuron with the ability to restore light adaptation mechanisms in retinal disorders such as Age Related Macular Degeneration, Diabetic Retinopathy, Glaucoma and Retinitis Pigmentosa. Our mission is to enable wireless and dynamic modulation of electrical synapses, offering a vast potential for transformative technologies and Intellectual Property assets.

Market Opportunity / Unmet Need:

One of the consequences of age related retinal degenerative conditions is so called "night-blindness", where patients are unable to see well under dark conditions. This deficit is present in a number of inherited degenerative conditions as well as age-related retinal dystrophies. It comes with a lot of unpleasant symptoms, such as loss of scotopic vision, disorientation, nausea, migraines caused by light, photophobia. Many of the issues are linked to aging, hence an expanding market: 18.7M patients in 2020 (growth rate CHER of). None of the vision restoration strategies on the market or in the clinic address this disorder, or the power of electrical synapse modulation in vision restoration.

Products / Services – Launched & Pipeline:

DopaVision: Light-sensitive Drug Delivery for multiple retinal indications (Provisional Patent Application Q2 2021, 21 years Runway)

Commercial / Technical Milestones:

The company was co-Founded in 2021 by Drs. Botir Sagdullaev and Cyril Eleftheriou after years of compelling research in the mechanisms of light adaptation and electrical-synapse circuit remodeling in retinal degeneration. Prototype completion Q2 2022. Clinical testing availability Q1 2024. Seeking strategic partnerships.

Competition / Competitive Advantages/ Customer Benefits:

Device Companies: Pixium Vision, Second Sight, Retina AG, Nano Retina
Therapeutic Companies: Regeneron, Novartis, Pfizer, Roche, Sparks Therapeutics, Gemeni Therapeutics, Ocular Therapeutix, PTC Therapeutics. DopaVision has the potential to integrate seamlessly with existing therapeutic and device vision restoration strategies, increasing their clinical results by up to a factor of 9. A strategic partnership with any of the top-tier vision restoration products would result in overall satisfaction for all stake holders: better vision for patients, lower reimbursements for insurance companies, and better products available to healthcare providers.

Exit Strategy: The synergistic and innovative nature of our product means its therapeutic value can unlock the potential of more traditional vision restoration approaches such as retinal implants or gene-therapy. We aim for a strategic acquisition with one of the major players in this field by H2 2024.